At the time of writing, Sage Therapeutics Inc [SAGE] stock is trading at $7.79, up 2.91%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The SAGE shares have gain 14.39% over the last week, with a monthly amount glided 3.87%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, RBC Capital Mkts downgraded its rating to Sector Perform on October 04, 2024, and dropped its price target to $4. On July 30, 2024, downgrade downgraded it’s rating to Hold and revised its price target to $10 on the stock. JP Morgan downgraded its rating to a Neutral and decreased its price target to $12 on July 25, 2024. Robert W. Baird initiated its recommendation with a Neutral and recommended $15 as its price target on May 29, 2024. Citigroup started tracking with a Sell rating for this stock on May 29, 2024, and assigned it a price target of $8. In a note dated April 17, 2024, BofA Securities downgraded an Underperform rating on this stock and revised its target price from $24 to $14.
For the past year, the stock price of Sage Therapeutics Inc fluctuated between $5.84 and $28.26. Currently, Wall Street analysts expect the stock to reach $45.22 within the next 12 months. Sage Therapeutics Inc [NASDAQ: SAGE] shares were valued at $7.79 at the most recent close of the market. An investor can expect a potential return of 480.49% based on the average SAGE price forecast.
Analyzing the SAGE fundamentals
According to Sage Therapeutics Inc [NASDAQ:SAGE], the company’s sales were 97.24M for trailing twelve months, which represents an 249.80% jump. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -4.96%, Pretax Profit Margin comes in at -4.58%, and Net Profit Margin reading is -4.58%. To continue investigating profitability, this company’s Return on Assets is posted at -0.64, Equity is -0.6 and Total Capital is -0.77. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.53 points at the first support level, and at 7.27 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.93, and for the 2nd resistance point, it is at 8.07.
Ratios To Look Out For
It is important to note that Sage Therapeutics Inc [NASDAQ:SAGE] has a current ratio of 9.95. In addition, the Quick Ratio stands at 9.95 and the Cash Ratio stands at 1.47. Considering the valuation of this stock, the price to sales ratio is 4.89, the price to book ratio is 0.76.
